T he treatment of substance use disorders (SUDs) is something of an orphan subspecialty that in Australia sits inconsistently between specialist generalists in General Practice and specialists in Addiction Medicine and Addiction Psychiatry. Where service and workforce planning exists it is similarly siloed, for example in the recent Australian Commonwealth Department of Health medical workforce planning 1 . As often happens, the Addiction Psychiatry data is lost in Psychiatry as a whole. In the absence of unified medical leadership advocating for coordinated treatment of SUDs, they can easily be sidelined, forgotten or viewed as "somebody else's problem". Even, or perhaps particularly, when specialist Dual Diagnosis workers or Alcohol and Other Drug Services do exist, SUDs are not considered part of core business for general psychiatry, rather the domain of the subspecialist only. Though it is widely acknowledged that Dual Diagnosis is the rule not the exception in psychiatry. This is not a new phenomenon, nor one confined to addiction services; similar problems affect eating disorders for example. This neglect or lack of 'ownership' of SUDs can lead to a deskilling of general services in recognising or managing SUDs.
The four themed articles in this issue and two in other sections illustrate that different manifestations of SUDs may present and need to be considered, recognised and managed, in all branches of psychiatry.
Many clinicians have been concerned by the rise in patients presenting with (meth)amphetamine-related psychoses. Australian data supports this impression, showing a significant increase in the number of New South Wales hospital separations for (meth)amphetamine-related conditions including amphetamine-related psychoses from 2010 to 2015 2 . When such patients present acutely, clinicians are presented with a diagnostic dilemma of differentiating acute stimulant intoxication with psychotic features from stimulant-induced psychotic disorder or schizophrenia relapse triggered by stimulant use. Both ICD-10 and DSM-5 separately describe all three conditions, but not necessarily in the same sections 3 , 4 . Recent work has suggested that there may be phenomenological differences between these diagnoses that can be discerned at initial presentation which may aid in making an initial diagnosis 5 , however in practice clinicians often rely on the urine drug screen (UDS) to look for recent stimulant use. Of course, prior work in this journal has suggested that in many common clinical situations UDS adds little to good history taking and interview skills 6 , but now in this issue we are given further evidence that results need to be interpreted with caution. Dadlani et al 7 highlight the risk that a common lipid-lowering drug can variably cause false positive UDS for amphetamines, depending on the specific assay used by the laboratory. This may be especially problematic for managing outpatients whose UDS may be undertaken by different laboratories on different occasions.
Obviously, a positive UDS may be useful in highlighting the possibility of acute intoxication causing psychotic symptoms or triggering a current relapse of schizophrenia. However, a negative result does not exclude a substance-induced psychosis, which may persist for up to 6 months 3 . Now Anderson et al 8 also remind us that the effects of prior substance use may persist well beyond the period of active use or UDS detection in other ways. They describe how perceptual disturbances related to prior substance use may be misdiagnosed as other psychiatric conditions, sometimes years later. This case highlights the need always to include a brief check for past SUDs in all patients.
Scott 9 demonstrates that the effects of SUDs can reach across the generations so that maternal alcohol use may also need to be considered. In his paper describing one specific forensic case where a diagnosis of Foetal Alcohol Spectrum Disorder (FASD) was considered relevant to an appeal, Scott draws attention to the general under-diagnosis of FASD and its expected high prevalence in the youth justice system. He also highlights the utility of the new Australian diagnostic guidelines 10 that are readily accessible and usable by any clinician. While Scott's paper highlights pre-natal alcohol as a potential cause of later psychiatric morbidity, the work of Iyer et al 11 focuses on the other common legal drug of dependence -tobacco. In the era of smoke-free hospitals and health campuses, this is one dependence and withdrawal state that all mental health clinicians need to know how to diagnose and treat. As discussed in this report "nicotine withdrawal symptoms can disguise or aggravate psychiatric conditions and impact the course of treatment". Sadly the assessment of nicotine dependence was found to be sub-optimally recorded in case notes and prescribing of nicotine replacement (NRT) was likely to result in many patients being under-dosed while inpatients. There is still a need to reinforce to all clinicians the importance of adequate NRT dosing, even though a straightforward algorithm has been available for more than a decade 12 .
Finally, to round off, there are two papers in this issue on general psychiatric topics where readers should also be prompted to consider possible SUDs comorbidity. Berling et al 13 on ECG and QTc measurement should encourage readers to consider if the patient is on medication-assisted treatment of opioid dependence with methadone as this can also contribute to QTc prolongation. In addition, Sapunov et al 14 on management of acute behavioural disturbance is relevant for considering behavioural disturbance in the context of acute stimulant intoxication. Readers would be well advised to consult local guidelines on acute behavioural management in this context.
As highlighted by the recent Australian Commonwealth Government planning exercise on the medical addiction workforce, there are significant areas of Australia with insufficient medical addiction specialists to manage patients with SUDs 1 . This requires that all psychiatrists need to be able to manage SUDs, especially in the acute phase of presentation to Mental Health Services.
Hopefully the themed articles in this issue will provide a starting point for some to explore this area anew and for others to broaden their knowledge.
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The extreme behaviours associated with acute amphetamine intoxication and withdrawal have been heavily dramatised and widely publicised by modern media, leading to political, legal, and social campaigns to limit their damaging consequences. These campaigns have included both medical and welfare supports aimed at harm reduction and legal and custodial approaches which attempt to reduce access and compel rehabilitation.
The February 2018 podcast interviews Dr Mark Daglish, Director of Addiction Psychiatry at Royal Brisbane and Women's Hospital. Dr Daglish has been involved in research into the neurochemistry of craving, the role of craving in relapse, and brief interventions for young people presenting to emergency departments with alcohol related injuries. In the podcast the importance of integrated care of patients presenting with addiction across medical, social, legal, and other services, and the search for maintenance treatments for stimulant users is discussed. Dr Daglish also mentions exploratory efforts to use psychoactive substances such as psilocybin to alter the natural history of addiction, speculating on the possibility of manufacturing the sort of epiphanies that can lead to abstinence. 
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